Journey Medical Corporation (NASDAQ: DERM) - Snapshot from 10‑Q (period ended June 30, 2025)
Quick take: Journey Medical's commercial-stage dermatology business shows revenue stability and an initial commercial ramp for newly approved Emrosi, but the company remains loss-making, carrying a sizabl...